Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 622 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening... January 22, 2026 More Evidence that One HPV Vaccine Dose Protects against Cancer-Causing Infections June 3, 2022 Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients... June 23, 2026 Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... July 28, 2021 Load more HOT NEWS “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... What to Do If You’ve Been Diagnosed With Cancer in the... Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia Two novel bispecific antibodies in combination with chemotherapy show efficacy in...
